Oncology
ASCO 2026: First to first line in HER-2 NSCLC, with Itziar C...
At ASCO 2026, BI Global Head of Oncology Itziar Canamasas spoke with pharmaphorum about the company's ASCO data and broader oncology strategy.
Digital
The future of feasibility: AI-driven site selection & protoc...
AI can help sponsors identify higher-potential sites, improve enrolment predictability, and accelerate study startup timelines.
R&D
Sponsored
Beyond weight loss: How obesity trial design is evolving
For many years, body weight sat at the centre of obesity drug development.
Patients
ASCO 26: Three cancer survivors share lessons for the field
In honour of National Cancer Survivors' Day, we recount three patient testimonies and calls to action from ASCO Voices at ASCO 2026.
Oncology
ASCO 2026: Chinese firms take a front seat in oncology, with...
Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.
Sales & Marketing
Digital
Market Access
Editor's Picks
Editor's Picks
